Protocol Ledger

NCT04777331 · Phase II · ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

Interventional Phase II clinical trial protocol NCT04777331 sponsored by Roche / Genentech in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-05 Enrollment: 586 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04777331
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)586 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04777331
Protocol FieldVerified Registry Value
NCT IdentifierNCT04777331
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment586 participants (ACTUAL)
Registered Start Date2021-05-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI